|
EP3177640B1
(en)
*
|
2014-08-08 |
2020-05-06 |
The Board of Trustees of the Leland Stanford Junior University |
High affinity pd-1 agents and methods of use
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
DK3298043T3
(da)
|
2015-05-18 |
2021-02-15 |
Ab Initio Biotherapeutics Inc |
SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
|
|
SG10201913573UA
(en)
|
2015-10-01 |
2020-03-30 |
Heat Biologics Inc |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
|
CA3042581A1
(en)
*
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
WO2018118887A1
(en)
*
|
2016-12-22 |
2018-06-28 |
Wake Forest University Health Sciences |
Sirp-gamma targeted agents for use in the treatment of cancer
|
|
US11299530B2
(en)
|
2017-01-05 |
2022-04-12 |
Kahr Medical Ltd. |
SIRP alpha-CD70 fusion protein and methods of use thereof
|
|
DK3565579T3
(da)
|
2017-01-05 |
2023-09-04 |
Kahr Medical Ltd |
Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
|
|
US11566060B2
(en)
|
2017-01-05 |
2023-01-31 |
Kahr Medical Ltd. |
PD1-CD70 fusion protein and methods of use thereof
|
|
ES2916217T3
(es)
|
2017-01-05 |
2022-06-29 |
Kahr Medical Ltd |
Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
|
|
KR102642385B1
(ko)
|
2017-02-06 |
2024-03-04 |
오리오니스 바이오사이언시스 엔브이 |
표적화된 키메라 단백질 및 이의 용도
|
|
CN110300764A
(zh)
*
|
2017-02-17 |
2019-10-01 |
Ose免疫疗法 |
抗SIRPg抗体的新用途
|
|
IL268198B2
(en)
|
2017-02-27 |
2024-10-01 |
Shattuck Labs Inc |
Tigit- and light-based chimeric proteins
|
|
US11267856B2
(en)
|
2017-02-27 |
2022-03-08 |
Shattuck Labs, Inc. |
CSF1R-CD40L chimeric proteins
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
CN108623689B
(zh)
*
|
2017-03-15 |
2020-10-16 |
宜明昂科生物医药技术(上海)有限公司 |
新型重组双功能融合蛋白及其制备方法和用途
|
|
PT3625259T
(pt)
|
2017-05-16 |
2024-07-04 |
Synthon Biopharmaceuticals Bv |
Anticorpos anti-sirpalfa
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
MX2020001309A
(es)
|
2017-08-02 |
2020-08-20 |
Phanes Therapeutics Inc |
Anticuerpos anti-cd47 y sus usos.
|
|
WO2019066536A1
(ko)
*
|
2017-09-28 |
2019-04-04 |
한국과학기술연구원 |
신규 암 치료용 조성물
|
|
US12110332B2
(en)
|
2017-11-20 |
2024-10-08 |
Taizhou Mabtech Pharmaceutical Co., Ltd. |
Bifunctional fusion protein targeting CD47 and PD-L1
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
CA3085693A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Adienne S.A. |
Quantitative cellular method for determining the biological activity of an anti-cd26 ligand
|
|
CA3104780A1
(en)
|
2018-07-11 |
2020-01-16 |
Kahr Medical Ltd. |
Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
|
|
IL280102B1
(en)
|
2018-07-11 |
2026-07-01 |
Kahr Medical Ltd |
Fusion protein containing PD1-4-1BBL and methods of using the same
|
|
EP3833391A4
(en)
|
2018-08-08 |
2022-08-10 |
Orionis Biosciences, Inc. |
ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF
|
|
US20230242640A1
(en)
*
|
2018-08-22 |
2023-08-03 |
Ose Immunotherapeutics |
ANTI-SIRPg Compounds
|
|
JP2022512540A
(ja)
|
2018-08-29 |
2022-02-07 |
シャタック ラボ,インコーポレイテッド |
Flt3l系キメラタンパク質
|
|
JP2021534769A
(ja)
*
|
2018-08-31 |
2021-12-16 |
エーエルエックス オンコロジー インコーポレイテッド |
デコイポリペプチド
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN109293778B
(zh)
*
|
2018-11-01 |
2021-09-17 |
浙江蓝盾药业有限公司 |
同时抗cd70和cd47的重链抗体及其制备方法和应用
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
CN113412279B
(zh)
|
2018-11-15 |
2024-09-24 |
拜奥迪斯私人有限公司 |
人源化抗SIRPα抗体
|
|
UA128431C2
(uk)
|
2018-11-26 |
2024-07-10 |
Форті Севен, Інк. |
ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
|
|
EP3936526A4
(en)
*
|
2019-03-06 |
2023-03-08 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE THEREOF
|
|
US11026973B2
(en)
|
2019-04-30 |
2021-06-08 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
KR20220012328A
(ko)
*
|
2019-05-24 |
2022-02-03 |
포티 세븐, 인코포레이티드 |
c-kit 및 CD47에 대한 면역요법제의 병용 투여를 위한 요법
|
|
EP3980747A1
(en)
*
|
2019-06-07 |
2022-04-13 |
ALX Oncology Inc. |
Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
|
|
MX2021015937A
(es)
|
2019-06-24 |
2022-02-03 |
Amgen Inc |
Inhibicion de sirp-gamma para el tratamiento del cancer.
|
|
WO2021046243A2
(en)
|
2019-09-03 |
2021-03-11 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
WO2021101966A1
(en)
*
|
2019-11-18 |
2021-05-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of fibrosis with combined blockade of il-6 and immune checkpoint
|
|
WO2021108693A1
(en)
|
2019-11-27 |
2021-06-03 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
JP2023528341A
(ja)
|
2020-06-01 |
2023-07-04 |
エーエルエックス オンコロジー インコーポレイテッド |
低メチル化剤を含むがんを治療するための併用療法
|
|
WO2022010806A1
(en)
|
2020-07-06 |
2022-01-13 |
ALX Oncology Inc. |
Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
|
|
WO2022048616A1
(zh)
*
|
2020-09-04 |
2022-03-10 |
江苏恒瑞医药股份有限公司 |
SIRPγ变体及其融合蛋白
|
|
EP4240367A4
(en)
|
2020-11-04 |
2024-10-16 |
Myeloid Therapeutics, Inc. |
MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2022120286A1
(en)
|
2020-12-06 |
2022-06-09 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
KR20220138909A
(ko)
|
2021-04-06 |
2022-10-14 |
주식회사 이뮤노로지컬디자이닝랩 |
Cd47에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
|
|
WO2022241029A1
(en)
|
2021-05-11 |
2022-11-17 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
JP2024520902A
(ja)
|
2021-05-13 |
2024-05-27 |
エーエルエックス オンコロジー インコーポレイテッド |
がんを治療するための併用療法
|
|
CA3253030A1
(en)
|
2022-06-01 |
2023-12-07 |
ALX Oncology Inc. |
Polytherapy for the treatment of urothelial carcinoma
|
|
KR102896511B1
(ko)
*
|
2022-09-07 |
2025-12-08 |
주식회사 시프트바이오 |
SIRPα 변이체에 특이적으로 결합하는 항체
|
|
EP4683654A1
(en)
*
|
2023-03-22 |
2026-01-28 |
Li, Wangzhi |
Sirp variants and uses thereof
|
|
EP4770665A1
(en)
|
2023-08-31 |
2026-07-08 |
Universität Basel Vizerektorat Forschung |
Chimeric antigen receptor constructs and uses thereof
|